发明公开
- 专利标题： USE OF NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH 5-HT3 RECEPTOR ANTAGONIST
-
申请号： EP21909544.5申请日： 2021-12-24
-
公开(公告)号： EP4268818A1公开(公告)日： 2023-11-01
- 发明人: XU, Daping , YANG, Changyong , LIAO, Cheng , ZHANG, Lianshan , HUANG, Jian
- 申请人： Shanghai Shengdi Pharmaceutical Co., Ltd , Shanghai Senhui Medicine Co., Ltd. , Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- 申请人地址： CN Shanghai 201210 No.1288 Haike Road Zhangjiang Town Pudong New District; CN Shanghai 201203 Floor 4, No.14 Building No.3728 Jinke Road Free Trade Pilot Zone Pudong New Area; CN Lianyungang, Jiangsu 222047 No. 7 Kunlunshan Road Economic and Technological Development Zone
- 代理机构： Regimbeau
- 优先权： CN202111066727 20210913
- 国际公布： WO2022135549 20220630
- 主分类号： A61K31/438
- IPC分类号： A61K31/438 ; A61P1/08 ; C07D471/10
摘要：
The present disclosure relates to the use of an NK1 antagonist prodrug compound and a 5-HT3 receptor antagonist. In particular, the present disclosure relates to the use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in combination with a 5-HT3 receptor antagonist in the preparation of a drug for preventing or treating nausea and/or vomiting.
信息查询
